Want to see JP:2160 full AI Analyst Report?
Top Page
GNI Group
(2160)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥2,492.00
▼(-26.05% Downside)
Action:Reiterated
Date:05/19/26
The score is held back primarily by weak recent profitability and negative operating/free cash flow despite strong revenue growth and a solid, low-leverage balance sheet. Technicals add additional pressure as the stock trades below major moving averages with negative momentum. Valuation is neutral at a ~26 P/E, offering limited offset without a provided dividend yield.
Positive Factors
Revenue Growth
Sustained TTM revenue growth of +76.5% indicates expanding product adoption and market traction. Over 2–6 months this supports operating leverage potential: if management converts top-line gains into controlled opex, the company can narrow losses and build a durable profit recovery path.
Negative Factors
Negative Cash Generation
Negative operating and free cash flow means the business currently consumes cash to run operations and invest, forcing reliance on reserves or financing. If negative cash generation persists over several quarters it raises funding, dilution and execution risk, constraining strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained TTM revenue growth of +76.5% indicates expanding product adoption and market traction. Over 2–6 months this supports operating leverage potential: if management converts top-line gains into controlled opex, the company can narrow losses and build a durable profit recovery path.
Read all positive factors
GNI Group (2160) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥159.60B
Dividend YieldN/A
Average Volume (3M)969.16K
Price to Earnings (P/E)―
Beta (1Y)1.20
Revenue Growth17.67%
EPS Growth-496.13%
CountryJP
Employees867
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-112.69
Shares Outstanding55,843,130
10 Day Avg. Volume1,104,200
30 Day Avg. Volume969,156
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)49.7
Revenue Forecast (FY)¥29.67B
GNI Group Business Overview & Revenue Model
Company Description
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently...
GNI Group Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.05B | 26.84B | 23.61B | 26.01B | 17.42B | 12.69B |
| Gross Profit | 19.90B | 19.99B | 18.04B | 22.43B | 14.74B | 11.09B |
| EBITDA | -3.92B | -1.76B | 2.67B | 14.47B | 2.16B | 2.14B |
| Net Income | -6.01B | -4.41B | 1.10B | 8.09B | 388.83M | 1.07B |
Balance Sheet | ||||||
| Total Assets | 82.59B | 83.79B | 71.94B | 64.27B | 33.91B | 30.30B |
| Cash, Cash Equivalents and Short-Term Investments | 19.87B | 21.10B | 12.93B | 23.15B | 11.24B | 14.35B |
| Total Debt | 5.17B | 5.37B | 22.66B | 18.84B | 537.36M | 1.13B |
| Total Liabilities | 32.07B | 32.11B | 32.07B | 27.72B | 14.10B | 11.03B |
| Stockholders Equity | 50.03B | 50.15B | 36.45B | 33.79B | 20.97B | 18.86B |
Cash Flow | ||||||
| Free Cash Flow | -2.93B | -2.74B | -3.69B | 5.28B | -580.20M | 172.78M |
| Operating Cash Flow | -2.54B | -2.41B | -3.16B | 6.55B | 393.32M | 552.27M |
| Investing Cash Flow | 592.26M | 2.73B | -12.89B | -3.33B | -4.12B | 2.24B |
| Financing Cash Flow | 11.02B | 10.47B | 3.22B | 7.17B | -646.33M | 357.06M |
GNI Group Technical Analysis
Positive
3370.00
Price Trends
2810.34
Positive
2921.05
Negative
2696.92
Positive
Market Momentum
-3.41
Negative
57.99
Neutral
86.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2160, the sentiment is Positive. The current price of 3370 is above the 20-day moving average (MA) of 2647.45, above the 50-day MA of 2810.34, and above the 200-day MA of 2696.92, indicating a bullish trend. The MACD of -3.41 indicates Negative momentum. The RSI at 57.99 is Neutral, neither overbought nor oversold. The STOCH value of 86.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2160.
GNI Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥24.93B | -33.43 | ― | ― | -11.11% | -187.80% | |
48 Neutral | ¥159.60B | -25.34 | -10.40% | ― | 17.67% | -496.13% | |
47 Neutral | ¥89.69B | -8.69 | -19.31% | ― | 10.88% | -327.56% | |
41 Neutral | ¥133.46B | -37.97 | -10.16% | ― | -59.19% | -124.16% | |
41 Neutral | ¥83.76B | -24.08 | -253.07% | ― | ― | 31.36% |
* Healthcare Sector Average
JP:2160
GNI Group
2,858.00
-227.00
-7.36%
JP:4587
Peptidream
1,028.00
-501.00
-32.77%
JP:4592
SanBio Co
1,073.00
-1,046.00
-49.36%
JP:4565
Sosei Group
970.00
115.00
13.45%
JP:7774
Japan Tissue Engineering Co., Ltd.
614.00
44.00
7.72%
GNI Group Corporate Events
GNI Sets July 1 Payment Date for Share Issue Funding AYUMI Acquisition
Jun 26, 2026
GNI Group has finalized key conditions in its previously announced plan to acquire all shares of AYUMI Pharmaceutical Holdings and convert it into a wholly owned subsidiary. The company will issue 9,974,291 new common shares via third-party allotm...
GNI Group Secures ¥20 Billion Covenant-Linked Loan for Ayumi Acquisition
Jun 26, 2026
GNI Group Ltd. has approved a new loan agreement with Mizuho Bank and SBI Shinsei Bank to secure ¥20 billion in short-term financing, primarily to fund the acquisition of Ayumi Pharmaceutical Holdings KK and related transaction expenses. The ...
GNI’s Gyre Therapeutics files Form S-3 tied to Cullgen acquisition
Jun 23, 2026
GNI Group has announced that its U.S. subsidiary Gyre Therapeutics has filed a Form S-3 registration statement with the SEC tied to its planned acquisition of Cullgen Inc. as a wholly owned subsidiary. The registration covers Gyre common shares to...
GNI Group Announces Transformational Acquisition of Ayumi Pharmaceutical Holdings
Jun 5, 2026
GNI Group Ltd. has announced a transformational acquisition of Ayumi Pharmaceutical Holdings, signaling a strategic move to expand its presence in the pharmaceutical industry. The deal is framed as a significant step in enhancing GNI’s portf...
GNI Group to Buy AYUMI Pharmaceutical Holdings and Issue New Shares to Bolster Japan Platform
Jun 5, 2026
GNI Group has agreed to acquire all shares of AYUMI Pharmaceutical Holdings KK, a Japan-based holding company with a strong sales network to medical institutions and a robust earnings base anchored by Calonal and other high-share products in ortho...
GNI Group to Gain New Largest Shareholder via AYUMI Pharma Deal
Jun 5, 2026
GNI Group has announced that BCP Asia AYM Holding (Cayman) L.P., an investment vehicle ultimately linked to Blackstone-managed private equity funds, is expected to become its new largest major shareholder. This shift will occur through a third-par...
GNI Group Outlines Q1 FY2026 Results and Financial Highlights
May 15, 2026
GNI Group has released its Q1 FY2026 financial results presentation, outlining segment performance, overall financial highlights, and supplementary materials for the period. While detailed figures are not disclosed in the text provided, the releas...
GNI Group Widens Q1 Loss as Drug Investment and Reorganization Weigh on Earnings
May 15, 2026
GNI Group reported first-quarter fiscal 2026 revenue of ¥5.53 billion, a modest 3.9% year-on-year increase, but posted a significantly wider operating loss of ¥2.75 billion and a net loss attributable to owners of the parent of ¥2.1...
GNI Group’s F351 Liver Fibrosis Drug Wins NDA Acceptance and Priority Review in China
May 12, 2026
GNI Group announced that its subsidiary Gyre Pharmaceuticals has received formal acceptance from China’s National Medical Products Administration for the New Drug Application of F351, or hydronidone, for chronic hepatitis B-induced liver fib...
Gyre Ramps Up F351 and Cullgen Investments as Q1 Swings to Loss
May 8, 2026
Gyre Therapeutics, a consolidated subsidiary of GNI Group, reported first-quarter fiscal 2026 revenue of US$22.5 million, essentially flat year on year, but swung from an operating profit of US$2.3 million to an operating loss of US$9.4 million. T...
GNI Group Reshapes Top Management as Gyre Advances Cullgen Acquisition
May 7, 2026
GNI Group has strengthened its management structure as Gyre Therapeutics, a consolidated subsidiary, advances the acquisition of Cullgen, with Gyre having filed a related report with the U.S. Securities and Exchange Commission. In tandem with this...
GNI Group’s Gyre Therapeutics Completes US$300 Million Cullgen Acquisition to Build Integrated U.S.-China Biopharma Platform
May 7, 2026
Gyre Therapeutics, a consolidated subsidiary of GNI Group, has completed the all-stock acquisition of clinical-stage biopharmaceutical firm Cullgen Inc., making it a wholly owned subsidiary in a deal valued at about US$300 million. The transaction...
GNI Group Starts Phase 2/3 Trial of Pirfenidone for Cancer-Related Lung Injury in China
Apr 20, 2026
GNI Group’s subsidiary Gyre Pharmaceuticals has enrolled the first patient in a Phase 2/3 clinical trial in China evaluating its self-developed pirfenidone capsules, Etuary, for the new indication of radiation-induced lung injury with or wit...
GNI Group Issues Revenue-Only Forecast for 2026 Amid Regulatory Uncertainty
Apr 1, 2026
GNI Group has for the first time released a revenue forecast for the fiscal year ending December 31, 2026, projecting consolidated sales of ¥27.2 billion based on existing businesses that are not contingent on regulatory outcomes. The guidanc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.